Welcome to our dedicated page for SAB Biotherapeutics SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company developing SAB-142 for type 1 diabetes and other autoimmune diseases. Form 8-K disclosures cover clinical presentations, Regulation FD materials, and material agreements, including manufacturing services for SAB-142.
The company’s filings also describe its capital structure and financing activity, including common stock, pre-funded warrants, public offering agreements and shelf registration use. Proxy materials cover annual meeting matters, director elections, board composition, stockholder voting items and related governance disclosures.
RTW Investments, LP and Roderick Wong, M.D. report their ownership in SAB Biotherapeutics, Inc. on an amended Schedule 13G. They beneficially own 1,587,302 shares of common stock, equal to 3.2% of the company.
The position reflects warrants held by RTW-managed funds to purchase Series A-3 Preferred Stock that is convertible into 1,587,302 common shares. RTW Investments and Dr. Wong share voting and dispositive power over these shares, which are held by the RTW funds. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of SAB Biotherapeutics.
SAB Biotherapeutics reported that its president and director Eddie Joe Sullivan received a grant of stock options on 02/03/2026. The award covers 3,000,000 options to buy common stock at an exercise price of $4.45 per share under the company’s 2021 Omnibus Equity Incentive Plan, as amended. These options vest over four years, with one quarter vesting on the first anniversary of the grant date and the remaining three quarters vesting in 36 equal monthly installments. Following this grant, Sullivan directly holds 3,000,000 derivative securities in the form of stock options.
SAB Biotherapeutics reported that CEO and director Samuel J. Reich received a grant of stock options on 02/03/2026. The award covers 4,800,000 options to buy common stock at an exercise price of $4.45 per share under the company’s 2021 Omnibus Equity Incentive Plan.
The options vest over four years, with one-quarter vesting on the first anniversary of the grant date and the remaining three-quarters vesting in 36 equal monthly installments. All 4,800,000 options are held directly by Reich and are scheduled to expire on 02/03/2036, aligning his potential compensation with longer-term company performance.
SAB Biotherapeutics reported that its Chief Operating Officer, Christoph Lawrence Bausch, received a grant of stock options. On 02/03/2026, he was awarded options to purchase 1,800,000 shares of common stock at an exercise price of $4.45 per share. These options were granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended. The award vests over four years, with one-quarter vesting on the first anniversary of the grant date and the remaining three-quarters vesting in 36 equal monthly installments thereafter. Following this grant, Bausch holds 1,800,000 stock options directly.
SAB Biotherapeutics reported an insider equity award for its Chief Medical Officer, Alexandra Kropotova. On February 3, 2026, she received a stock option grant covering 2,400,000 shares of common stock under the company’s 2021 Omnibus Equity Incentive Plan.
The option has an exercise price of $4.45 per share. The underlying shares vest over four years: one quarter of the grant vests on the first anniversary of the grant date, and the remaining three quarters vest in 36 equal monthly installments thereafter. Following this grant, she beneficially holds options on 2,400,000 shares, all directly owned.
SAB Biotherapeutics reported a new equity award for its Chief Financial Officer, Lucy To. On 02/03/2026, she received a stock option covering 2,400,000 shares of common stock under the company’s 2021 Omnibus Equity Incentive Plan, as amended.
The option has an exercise price of $4.45 per share. The shares underlying the option vest over four years, with 1/4 vesting on the one-year anniversary of the grant date and the remaining 3/4 vesting in 36 equal monthly installments thereafter. After this grant, she beneficially owns 2,400,000 derivative securities directly.
SAB Biotherapeutics, Inc. is the subject of a Schedule 13G showing that Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman collectively report beneficial ownership of 3,471,861 shares of SAB’s common stock, representing 7.3% of the class.
The Master Fund directly holds the 3,471,861 shares, and the ownership percentage is based on 47,606,851 outstanding shares as of November 10, 2025, as disclosed in SAB’s Form 10-Q. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, share voting and dispositive power over these shares. The filers certify the position was not acquired to change or influence control of SAB Biotherapeutics.
SAB Biotherapeutics, Inc. reported that on January 12, 2026 it posted an updated corporate presentation on its official website. The presentation, dated January 12, 2026 and referenced as Exhibit 99.1, is intended for investors and other stakeholders seeking an overview of the company and its plans. The disclosure notes that this presentation is being furnished rather than filed under securities laws, meaning it is not automatically incorporated into other regulatory documents unless specifically referenced.
SAB Biotherapeutics, Inc. granted director Rita Jain a new equity award. On January 5, 2026, she received a stock option to purchase 240,000 shares of common stock at an exercise price of $3.74 per share. This represents her inaugural grant as a member of the company’s Board of Directors.
The option expires on January 5, 2036 and the underlying shares vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029. The award was made under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended, and is held directly by Jain.